Logo image
Anticoagulation practices associated with bleeding and thrombosis in pediatric extracorporeal membrane oxygenation; a multi-center secondary analysis
Journal article   Peer reviewed

Anticoagulation practices associated with bleeding and thrombosis in pediatric extracorporeal membrane oxygenation; a multi-center secondary analysis

David K Bailly, Ron W Reeder, Jennifer A Muszynski, Kathleen L Meert, Ashish A Ankola, Peta MA Alexander, Murray M Pollack, Frank W Moler, Robert A Berg, Joseph Carcillo, …
Perfusion (United Kingdom), Vol.38(2)
2023

Abstract

Anticoagulants Child Extracorporeal Membrane Oxygenation Fibrinogen Hemorrhage Heparin Humans Retrospective Studies Thrombosis fibrinogen heparin anticoagulant agent heparin activated partial thromboplastin time adult anticoagulation Article bleeding blood clotting time blood transfusion brain hemorrhage cardiopulmonary bypass cardiovascular disease child erythrocyte transfusion extracorporeal oxygenation hematocrit hospital discharge hospitalization human infant intensive care unit length of stay limb ischemia lung embolism lung hemorrhage major clinical study male multicenter study outcome assessment pediatric intensive care unit perioperative period platelet count prospective study prothrombin time resuscitation risk factor secondary analysis thrombocyte transfusion thrombosis adverse event bleeding clinical trial retrospective study thrombosis
To determine associations between anticoagulation practices and bleeding and thrombosis during pediatric extracorporeal membrane oxygenation (ECMO), we performed a secondary analysis of prospectively collected data which included 481 children (<19 years), between January 2012 and September 2014. The primary outcome was bleeding or thrombotic events. Bleeding events included a blood product transfusion >80 ml/kg on any day, pulmonary hemorrhage, or intracranial bleeding, Thrombotic events included pulmonary emboli, intracranial clot, limb ischemia, cardiac clot, and arterial cannula or entire circuit change. Bleeding occurred in 42% of patients. Five percent of subjects thrombosed, of which 89% also bled. Daily bleeding odds were independently associated with day prior activated clotting time (ACT) (OR 1.03, 95% CI= 1.00, 1.05, p=0.047) and fibrinogen levels (OR 0.90, 95% CI 0.84, 0.96, p <0.001). Thrombosis odds decreased with increased day prior heparin dose (OR 0.88, 95% CI 0.81, 0.97, p=0.006). Lower ACT values and increased fibrinogen levels may be considered to decrease the odds of bleeding. Use of this single measure, however, may not be sufficient alone to guide optimal anticoagulation practice during ECMO. © The Author(s) 2022.

Metrics

4 Record Views

Details

Logo image